SCHEMBL3078166

SCHEMBL3078166

CC(C)(C)NS(=O)(=O)c1ccc(N)c(C2=CCCCC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PTGS2 P35354 2/20 0.42
MAPT P10636 3/20 0.40
KDM4E B2RXH2 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 2/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
NSD2 O96028 2/20 0.37
PIK3CD O00329 1/20 0.37
PIK3CG P48736 1/20 0.37
ALDH1A1 P00352 4/20 0.37
JAK2 O60674 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14392178 0.84 GFER (0.43) MEN1KMT2APTGS2MAPTKDM4E
SCHEMBL3096054 0.81 PARG (0.44) PARGMEN1KMT2AMAPTKDM4E
SCHEMBL3078707 0.79 CSF1R (0.42) PTGS2HDAC3HDAC1HDAC2CSF1R
SCHEMBL31122048 0.78 MEN1 (0.47) PARGMEN1KMT2APTGS2MAPT
SCHEMBL772426 0.78 MEN1 (0.47) PARGMEN1KMT2APTGS2MAPT
SCHEMBL5654006 0.77 CSF1R (0.52) PTGS2HDAC3HDAC1HDAC2CSF1R
SCHEMBL3091470 0.75 PTGS2 (0.37) PTGS2HDAC3HDAC1HDAC2
Trifluoroacetic Acid SCHEMBL3082964 0.73 PTGS2 (0.46) MEN1KMT2APTGS2MAPTKDM4E
SCHEMBL3084303 0.72 CSF1R (0.52) MEN1KMT2APTGS2MAPTALDH1A1
SCHEMBL3070907 0.72 PSMB5 (0.37) PTGS2HDAC3HDAC1HDAC2CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER PARG 4373/4885MEN1 1293/4885KMT2A 990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.